CJRB 202
Alternative Names: CJRB-202Latest Information Update: 31 Aug 2023
At a glance
- Originator CJ Bioscience
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 08 Aug 2023 CJRB 202 is available for licensing as of 08 Aug 2023. https://www.cjbioscience.com/pipeline
- 27 Jul 2023 Preclinical trials in Inflammatory bowel diseases in South Korea (unspecified route) before July 2023 (CJ Biosciences pipeline, July 2023)